Skip to main content

211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.

Publication ,  Journal Article
Larsen, RH; Murud, KM; Akabani, G; Hoff, P; Bruland, OS; Zalutsky, MR
Published in: J Nucl Med
July 1999

UNLABELLED: Bisphosphonates were synthesized for use as carriers for astatine and iodine radioisotopes to target bone neoplasms. METHODS: Radiohalogenated activated esters were coupled to the amino group in the side chain of the bisphosphonate. The bisphosphonate 3-amino-1-hydroxypropylidene bisphosphonate was combined with four different acylation agents: N-succinimidyl 3-[211At]astatobenzoate, N-succinimidyl 3-[131I]iodobenzoate, N-succinimidyl-5-[211At]astato-3-pyridinecarboxylate and N-succinimidyl-5-[131I]iodo-5-pyridinecarboxylate. The products, 3-[131I]iodobenzamide-N-3-hydroxypropylidene-3,3-bisphosphonate (IBPB), 3-[211At]astato-benzamide-N-3-hydroxypropylidene-3,3-bisphosphonat e (ABPB), 5-[131I]iodopyridine-3-amide-N-3-hydroxypropylidene-3,3-bisphospho nate (IPPB) and 5-[211At]astatopyridine-3-amide-N-3-hydroxypropylidene-3,3-bisphos phonate (APPB), were injected intravenously into Balb/c mice. MIRD and Monte Carlo methods were used on the basis of cumulated activity calculated from biodistribution data to estimate dose to organs and bone segments. RESULTS: All 131I- and 211At-labeled analogs were strongly incorporated into osseous tissue and retained there at stable levels, while a rapid clearance from blood was observed. The bone uptake was found to be similar for 211At- and 131I-labeled bisphosphonate when compared in paired label experiments. Bone uptake and bone-to-tissue ratios were better for IBPB compared with IPPB, and ABPB compared with APPB. All four compounds appeared to be highly resistant to in vivo dehalogenation as indicated by low uptake of 131I/211At in the thyroid gland and stomach. According to dosimetric estimates, the bone surface-to-bone marrow ratio was three times higher with 211At than with 131I. CONCLUSION: Both the beta-particle- and alpha-particle-emitting compounds showed high in vivo stability and excellent affinity for osseous tissue. Further preclinical evaluation is therefore warranted.

Duke Scholars

Published In

J Nucl Med

ISSN

0161-5505

Publication Date

July 1999

Volume

40

Issue

7

Start / End Page

1197 / 1203

Location

United States

Related Subject Headings

  • Tissue Distribution
  • Time Factors
  • Nuclear Medicine & Medical Imaging
  • Mice, Inbred BALB C
  • Mice
  • Male
  • Isotope Labeling
  • Iodine Radioisotopes
  • Diphosphonates
  • Bone and Bones
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Larsen, R. H., Murud, K. M., Akabani, G., Hoff, P., Bruland, O. S., & Zalutsky, M. R. (1999). 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med, 40(7), 1197–1203.
Larsen, R. H., K. M. Murud, G. Akabani, P. Hoff, O. S. Bruland, and M. R. Zalutsky. “211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.J Nucl Med 40, no. 7 (July 1999): 1197–1203.
Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med. 1999 Jul;40(7):1197–203.
Larsen, R. H., et al. “211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.J Nucl Med, vol. 40, no. 7, July 1999, pp. 1197–203.
Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med. 1999 Jul;40(7):1197–1203.

Published In

J Nucl Med

ISSN

0161-5505

Publication Date

July 1999

Volume

40

Issue

7

Start / End Page

1197 / 1203

Location

United States

Related Subject Headings

  • Tissue Distribution
  • Time Factors
  • Nuclear Medicine & Medical Imaging
  • Mice, Inbred BALB C
  • Mice
  • Male
  • Isotope Labeling
  • Iodine Radioisotopes
  • Diphosphonates
  • Bone and Bones